KazemianPSheblFMMcCannNWalenskyRPWexlerDJ. Evaluation of the cascade of diabetes care in the united states, 2005-2016. JAMA Intern Med. 2019;179(10):1376-1385.
2.
ArnoldSVGoyalAInzucchiSE, et al. Quality of care of the initial patient cohort of the Diabetes Collaborative Registry(®). J Am Heart Assoc. 2017;6(8):e005999.
3.
BlondeLMeneghiniLPengXV, et al. Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA. Diabetes Ther. 2018;9(3):1347-1358.
4.
DalalMRGrabnerMBonineNStephensonJJDiGenioABieszkN. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. Diabetes Res Clin Pract. 2016;121:17-26.
5.
WuNAagrenMBoulangerLFriedmanMWilkeyK. Assessing achievement and maintenance of glycemic control by patients initiating basal insulin. Curr Med Res Opin. 2012;28(10):1647-1656.
6.
PatelDTriplittCTrujilloJ. Appropriate titration of basal insulin in type 2 diabetes and the potential role of the pharmacist. Adv Ther. 2019;36(5):1031-1051.
CowartKUpdikeWHPathakR. Prevalence of and characteristics associated with overbasalization among patients with type 2 diabetes using basal insulin: a cross-sectional study. Clin Diabetes. 2021;39(2):173-175.doi:10.2337/cd20-0080
9.
MeeceJ. Basal insulin intensification in patients with type 2 diabetes: a review. Diabetes Ther. 2018;9(3):877-890. doi:10.1007/s13300-018-0395-3
10.
CavalotFPagliarinoAValleM, et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care. 2011;34(10):2237-2243.
11.
TakaoTSukaMYanagisawaHIwamotoY. Impact of postprandial hyperglycemia at clinic visits on the incidence of cardiovascular events and all-cause mortality in patients with type 2 diabetes. J Diabetes Investig. 2017;8(4):600-608.
12.
HanssenNMJKraakmanMJFlynnMCNagareddyPRSchalkwijkCGMurphyAJ. Postprandial glucose spikes, an important contributor to cardiovascular disease in diabetes?Front Cardiovasc Med. 2020;18(7):570553.
13.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes - 2021. Diabetes Care. 2021;44(suppl 1):S111-S124.
14.
GarberAJHandelsmanYGrunbergerG, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107-139.
15.
ReidTGaoLGillJ, et al. How much is too much? Outcomes in patients using high-dose insulin glargine. Int J Clin Pract. 2016;70(1):56-65.
16.
GoldenbergRMBerardL. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. Curr Med Res Opin. 2018;34(1):1-10.
17.
DavidJFonsecaV. When should fixed ratio basal insulin/glucagon-like peptide-1 receptor agonists combination products be considered?J Diabetes Complications. 2019;33(12):107473.
18.
JohnsonELFriasJPTrujilloJM. Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin. Postgrad Med. 2018;130(4):365-374.
19.
LaSalleJRBerriaR. Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other health care professionals. J Am Osteopath Assoc. 2013;113(2):152-162.
20.
ShubrookJH. Insulin for type 2 diabetes: how and when to get started. J Fam Pract. 2014;63(2):76-81.
21.
ZismanADexTRobertsMSaremiAChaoJArodaVR. Bedtime-to-morning glucose difference and iGlarLixi in type 2 diabetes: post hoc analysis of LixiLan-L. Diabetes Ther. 2018;9(5):2155-2162.
22.
ZismanAMoralesFStewartJStuhrAVlajnicAZhouR. BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin. BMJ Open Diabetes Res Care. 2016;4(1):e000171.
23.
ChoiJHParkCYChaBS, et al. Perception of clinicians and diabetic patients on the importance of postprandial glucose control and diabetes education status: a cross sectional survey. Diabetes Metab J. 2012;36(2):120-127.
24.
ChunJHO’NeillMS. Optimizing diabetes care with the standardized continuous glucose monitoring report. Clin Diabetes. 2020:38(2):194-200. doi:10.2337/cd19-0066
25.
American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes - 2021. Diabetes Care. 2021;44(suppl 1):S85-S99.
26.
Doyle-DelgadoKChamberlainJJ. Use of diabetes-related applications and digital health tools by people with diabetes and their health care providers. Clin Diabetes. 2020;38(5):449-461. doi:10.2337/cd20-0046
27.
FlemingGAPetrieJRBergenstalRMHollRWPetersALHeinemannL. Diabetes digital app technology: benefits, challenges, and recommendations. a consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care. 2020;43(1):250-260.
28.
ChoudharyP. Continuous subcutaneous insulin infusion for type 2 diabetes. Lancet. 2014;384(9950):1240-1242.
29.
CuiLSchroederPRSackPA. Inpatient and outpatient technologies to assist in the management of insulin dosing. Clin Diabetes. 2020;38(5):462-473. doi:10.2337/cd20-0054
30.
HeileMHollsteggeBBroxtermanLCaiACloseK. Automated insulin delivery: easy enough to use in primary care?Clin Diabetes. 2020;38(5):474-485. doi:10.2337/cd20-0050.
